| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SN-38 | GDSC1000 | pan-cancer | AAC | -0.037 | 0.3 |
| mRNA | OSI-906 | CTRPv2 | pan-cancer | AAC | 0.039 | 0.3 |
| mRNA | GSK269962A | GDSC1000 | pan-cancer | AAC | -0.036 | 0.3 |
| mRNA | staurosporine | CTRPv2 | pan-cancer | AAC | -0.084 | 0.3 |
| mRNA | BRD-K27188169 | CTRPv2 | pan-cancer | AAC | -0.059 | 0.3 |
| mRNA | salermide | CTRPv2 | pan-cancer | AAC | 0.049 | 0.3 |
| mRNA | FH535 | GDSC1000 | pan-cancer | AAC | 0.038 | 0.3 |
| mRNA | pifithrin-mu | CTRPv2 | pan-cancer | AAC | -0.038 | 0.3 |
| mRNA | GSK1059615 | CTRPv2 | pan-cancer | AAC | -0.049 | 0.3 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.04 | 0.3 |